The estimated Net Worth of Joshua Reed is at least 2.4 百万$ dollars as of 5 September 2019. Mr. Reed owns over 3,200 units of Aldeyra Therapeutics Inc stock worth over 221,441$ and over the last 6 years he sold ALDX stock worth over 0$. In addition, he makes 2,181,280$ as Chief Financial Officer at Aldeyra Therapeutics Inc.
Joshua has made over 1 trades of the Aldeyra Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 3,200 units of ALDX stock worth 15,072$ on 5 September 2019.
The largest trade he's ever made was buying 3,200 units of Aldeyra Therapeutics Inc stock on 5 September 2019 worth over 15,072$. On average, Joshua trades about 320 units every 0 days since 2018. As of 5 September 2019 he still owns at least 35,774 units of Aldeyra Therapeutics Inc stock.
You can see the complete history of Mr. Reed stock trades at the bottom of the page.
Joshua Reed serves as Chief Financial Officer of the Company. Mr. Reed has more than 20 years of financial operations, strategy, and investment banking experience. Prior to joining Aldeyra, from June 2016 to July 2018, Mr. Reed served as Vice President and Head of Finance for Bristol-Myers Squibb’s (BMS) United States and Puerto Rico operations, a $12 billion business unit from September 2013 to June 2016, Mr. Reed served as Executive Director, Corporate Financial Analysis for BMS Prior to that, Mr. Reed held roles of increasing responsibility at BMS, including positions in financial planning and analysis, supply chain finance, operations finance, and mergers and acquisitions. Prior to that, Mr. Reed was the Vice President, Strategic Business Development at JPMorgan Chase, and held investment banking positions at Credit Suisse First Boston, where he focused on mergers and acquisitions. Mr. Reed received a B.S. in Finance from Rutgers University and an M.B.A. with concentrations in Finance and Corporate Strategy from the University of Michigan’s Ross School of Business.
As the Chief Financial Officer of Aldeyra Therapeutics Inc, the total compensation of Joshua Reed at Aldeyra Therapeutics Inc is 2,181,280$. There are 1 executives at Aldeyra Therapeutics Inc getting paid more, with Todd Brady having the highest compensation of 4,141,260$.
Joshua Reed is 47, he's been the Chief Financial Officer of Aldeyra Therapeutics Inc since 2018. There are 11 older and 3 younger executives at Aldeyra Therapeutics Inc. The oldest executive at Aldeyra Therapeutics Inc is Jesse Treu, 73, who is the Independent Director.
Over the last 11 years, insiders at Aldeyra Therapeutics Inc have traded over 6,285,725$ worth of Aldeyra Therapeutics Inc stock and bought 11,547,153 units worth 75,179,936$ . The most active insiders traders include Advisors Llcperceptive Life...、& Johnson Johnson & Johnson...、Advisors Llcedelman Josephp.... On average, Aldeyra Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of 1,358,662$. The most recent stock trade was executed by Stephen Machatha on 12 August 2024, trading 16,041 units of ALDX stock currently worth 76,034$.
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
Aldeyra Therapeutics Inc executives and other stock owners filed with the SEC include: